Search results
Results From The WOW.Com Content Network
In the United States, a boxed warning (sometimes "black box warning", colloquially) is a type of warning that appears near the beginning of the package insert for certain prescription drugs, so called because the U.S. Food and Drug Administration specifies that it is formatted with a 'box' or border around the text [1] to emphasize its ...
For example, the CHOP regimen consists of cyclophosphamide, doxorubicin, vincristine and prednisone. Besides chemotherapy, medical oncology ( pharmacotherapy for cancer) includes several noncytotoxic classes of therapy, such as hormonal therapy and targeted therapy (biologic therapy).
Cyclophosphamide (CP), also known as cytophosphane among other names, [3] is a medication used as chemotherapy and to suppress the immune system. [4] As chemotherapy it is used to treat lymphoma , multiple myeloma , leukemia , ovarian cancer , breast cancer , small cell lung cancer , neuroblastoma , and sarcoma . [ 4 ]
The US Food and Drug Administration has placed its most serious warning — a so-called black-box warning — on a drug used to relieve menopausal hot flashes.
Obinutuzumab has two black box warnings: hepatitis B reactivation and progressive multifocal leukoencephalopathy. [7] [5]In the clinical trial of obinutuzumab in combination with chlorambucil, participants experienced infusion reactions (69%; 21% grade 3/4), neutropenia (40%; 34% grade 3/4), thrombocytopenia (15%; 11% grade 3/4), anemia (12%), and pyrexia and cough (10% each).
Brentuximab vedotin [6] consists of the chimeric monoclonal antibody brentuximab (cAC10, which targets the cell-membrane protein CD30) linked with maleimide attachment groups, cathepsin-cleavable linkers (valine-citrulline), and para-aminobenzylcarbamate spacers to three to five units of the antimitotic agent monomethyl auristatin E (MMAE, reflected by the 'vedotin' in the drug's name). [7]
Idelalisib, sold under the brand name Zydelig, is a medication used to treat certain blood cancers. [5] [4] Idelalisib acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase. [7] [8] It was developed by Gilead Sciences. It is taken orally (swallowed by mouth).
In 2002 the United States Food and Drug Administration (FDA) obligated BMS to add a black box warning about potential fatal liver toxicity to the drug label. [ 43 ] [ 13 ] Worldwide sales in 2002 were $409 million.